.png "Biogen Inc (NASDAQ: BIIB)")
In a report issued on January 7, Cory Kasimov from J.P. Morgan maintained a Buy rating on Biogen Inc (BIIB). The company’s shares closed yesterday at $326.63.
According to TipRanks.com, Kasimov is a 2-star analyst with an average return of -0.2% and a 38.7% success rate. Kasimov covers the Healthcare sector, focusing on stocks such as ACADIA Pharmaceuticals Inc, Allogene Therapeutics Inc, and Global Blood Therapeutics.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Biogen Inc with a $379.06 average price target, representing a 16.1% upside. In a report issued on December 24, Nomura also reiterated a Buy rating on the stock with a $420 price target.
.
See today’s analyst top recommended stocks >>
The company has a one-year high of $388.67 and a one-year low of $249.17. Currently, Biogen Inc has an average volume of 1.34M.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Biogen, Inc. is a biopharmaceutical company, which engages in discovering, developing, and delivering therapies for neurological and neurodegenerative diseases. It offers TECFIDERA, AVONEX, PLEGRIDY, TYSABRI, ZINBRYTA, and FAMPYRA for the treatment of multiple sclerosis; SPINRAZA for the treatment of spinal muscular atrophy; and FUMADERM for the treatment of severe plaque psoriasis. The company was founded by Charles Weissmann, Heinz Schaller, Kenneth Murray, Walter Gilbert, and Phillip Allen Sharp in 1978 and is headquartered in Cambridge, MA.
